Fig. 2: SRPK1 upregulation inhibits gefitinib-induced apoptosis in NSCLC cell lines. | Oncogene

Fig. 2: SRPK1 upregulation inhibits gefitinib-induced apoptosis in NSCLC cell lines.

From: Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer

Fig. 2

A GO analysis of proteins enriched by SRPK1 antibodies after IP-MASS assays revealed the biological processes associated with SRPK1 interactions. B Western blot analysis confirmed SRPK1 overexpression in gefitinib-sensitive NCI-H1650 and PC9 cells, and SRPK1 downregulation in gefitinib-resistant NCI-H1975 and PC9GR cells. C Verification of IC50 values at a range of gefitinib concentrations (0, 0.01, 0.1, 2,5, 10, 20, 30, 40 µM) in the indicated cells (n = 3). The percentages of (D) apoptotic and (E) TUNEL+ cells following gefitinib treatment. F Bcl-xL, Bcl-xS, cleaved caspase-3, and cleaved PARP1 protein expression in the indicated cell lines following treatment with gefitinib (0, 1, 5, 10, 20 µM); β-tubulin serves as a loading control. Data represent the mean ± SD (n = 3). **P < 0.01, ***P < 0.001.

Back to article page